Allergic Bronchopulmonary Aspergillosis
27
6
7
13
Key Insights
Highlights
Success Rate
87% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
7.4%
2 terminated out of 27 trials
86.7%
+0.2% vs benchmark
15%
4 trials in Phase 3/4
38%
5 of 13 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 13 completed trials
Clinical Trials (27)
Real-World Effectiveness of Benralizumab in Allergic Bronchopulmonary Aspergillosis
A Cohort Study of the Efficacy and Safety of Biologics in Patients With ABPA
A Study of the Efficacy and Safety of Bronchoscopic Airway Clearance and Amphotericin B Spraying in Patients With ABPA
iMagIng pulmonaRy Aspergillosis Using Gallium-68-dEferoxamine
Investigating Treatment With Dupilumab in Patients With Allergic Bronchopulmonary Aspergillosis (ABPA) (LIBERTY ABPA AIRED)
Deflazacort Vs. Prednisolone in Acute-stage ABPA
A Randomized Trial of Prednisolone, Itraconazole, or Their Combination in Allergic Bronchopulmonary Aspergillosis
Voriconazole Inhalation Powder for the Treatment of Pulmonary Aspergillosis
Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment
Multicenter Registration Study on Allergic Bronchopulmonary Aspergillosis
Immune Profiles in CF Fungal Infection
Oral Itraconazole Versus Combination of Systemic Glucorticoids and Oral Itraconazole in CPA-ABPA Overlap Syndrome
Allergic Bronchopulmonary Aspergillosis Prescreening Study
A Randomized Trial of Itraconazole in Acute Stages of Allergic Bronchopulmonary Aspergillosis
Benralizumab in the Treatment of Patients With Severe Asthma With ABPA
A Prospective Study on Optimizing Treatment for ABPA
Phase 1 Three Part SAD, MAD & Cross-Over Study of ZP-059 in Healthy and Asthmatic Subjects
Study in Adult Asthmatic Patients With Allergic Bronchopulmonary Aspergillosis
Evaluation of a Therapeutic Strategy Including Nebulised Liposomal Amphotericin B (Ambisome®) in Maintenance Treatment of Allergic Bronchopulmonary Aspergillosis (Cystic Fibrosis Excluded).
Protocol TARC-ABPA